Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC)
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2009-11-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 4
- Registration Number
- NCT00494026
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wolverhampton, West Midlands, United Kingdom
Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer
- Conditions
- Bladder Cancer
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2007-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 2
- Registration Number
- NCT00490880
- Locations
- 🇵🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland
Trial of Perioperative Chemotherapy (Gemcitabine and Cisplatin) and Adjuvant Chemoradiotherapy (With Weekly Low Dose Gemcitabine) in Patients With Lung Cancer With Positive Nodes
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2007-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 13
- Registration Number
- NCT00490659
- Locations
- 🇵🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland
Intravesical Chemotherapy Treatment of Superficial Bladder Cancer
- Conditions
- Bladder Neoplasms
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2007-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 8
- Registration Number
- NCT00491114
- Locations
- 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Varese, Italy
Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer
- Conditions
- Epithelial Ovarian Cancer
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2007-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 7
- Registration Number
- NCT00490711
- Locations
- 🇸🇰
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bratislava, Slovakia
Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2007-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 10
- Registration Number
- NCT00491127
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain
A Study for Patients With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Human Insulin Inhalation PowderDrug: Neutral protamine hagedorn insulin
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2008-07-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 129
- Registration Number
- NCT00490854
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toyama, Japan
Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 52
- Registration Number
- NCT00490373
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany
Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency
- Conditions
- Hypopituitarism
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 387
- Registration Number
- NCT00490191
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, Lancashire, United Kingdom
Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas
- Conditions
- Biliary Tract Carcinoma
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 39
- Registration Number
- NCT00490399
- Locations
- 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of